In critically ill patients with COVID-19, do the IL-6 receptor antagonists, tocilizumab and sarilumab, compared with standard care, improve respiratory and cardiovascular organ support free days up to day 21?
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed